{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:00:08Z","timestamp":1791932408662,"version":"4.3.4"},"reference-count":134,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"unspecified","delay-in-days":553,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["Clinical Leave Stipend"],"award-info":[{"award-number":["Clinical Leave Stipend"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2019,10,3]]},"DOI":"10.1080\/21645515.2019.1649532","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T10:48:25Z","timestamp":1564656505000},"page":"2269-2285","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":92,"title":["Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-9471","authenticated-orcid":false,"given":"Anahita","family":"Fathi","sequence":"first","affiliation":[{"name":"University Medical-Center Hamburg-Eppendorf","place":["Hamburg, Germany"]},{"name":"Bernhard Nocht Institute for Tropical Medicine","place":["Hamburg, Germany"]},{"name":"German Center for Infection Research, Hamburg-L\u00fcbeck-Borstel-Riems","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2056-9195","authenticated-orcid":false,"given":"Christine","family":"Dahlke","sequence":"additional","affiliation":[{"name":"University Medical-Center Hamburg-Eppendorf","place":["Hamburg, Germany"]},{"name":"Bernhard Nocht Institute for Tropical Medicine","place":["Hamburg, Germany"]},{"name":"German Center for Infection Research, Hamburg-L\u00fcbeck-Borstel-Riems","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marylyn M.","family":"Addo","sequence":"additional","affiliation":[{"name":"University Medical-Center Hamburg-Eppendorf","place":["Hamburg, Germany"]},{"name":"Bernhard Nocht Institute for Tropical Medicine","place":["Hamburg, Germany"]},{"name":"German Center for Infection Research, Hamburg-L\u00fcbeck-Borstel-Riems","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"WHO. Ten threats to global health in 2019 [Internet]. [accessed 2019 Apr 3]. https:\/\/www.who.int\/emergencies\/ten-threats-to-global-health-in-2019"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2018.031"},{"key":"e_1_3_3_4_1","unstructured":"WHO. WHO Director-General summarizes the outcome of the emergency committee regarding clusters of microcephaly and Guillain-Barr\u00e9 syndrome [Internet]. [accessed 2019 Apr 3]. https:\/\/www.who.int\/en\/news-room\/detail\/01-02-2016-who-director-general-summarizes-the-outcome-of-the-emergency-committee-regarding-clusters-of-microcephaly-and-guillain-barr\u00e9-syndrome"},{"key":"e_1_3_3_5_1","unstructured":"WHO. WHO publishes list of top emerging diseases likely to cause major epidemics [Internet]. 2015 [accessed 2019 Mar 24]. https:\/\/www.who.int\/medicines\/ebola-treatment\/WHO-list-of-top-emerging-diseases\/en\/"},{"key":"e_1_3_3_6_1","unstructured":"WHO. Methodology for prioritizing severe emerging diseases for research and development background [Internet]. 2017 [accessed 2019 Jun 27]. http:\/\/www.who.int\/csr\/research-and-development\/meeting-report-prioritization.pdf?ua=1"},{"key":"e_1_3_3_7_1","unstructured":"WHO. WHO research and development blueprint 2018 annual review of diseases prioritized under the research and development blueprint informal consultation [internet]. [accessed 2019 Jun 28]. http:\/\/www.who.int\/csr\/research-and-development\/documents\/prioritizing_diseases_progress\/en\/"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-7032-1_4"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/02648725.2018.1474320"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.10.4477"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.5.3723-3732.1999"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01911-06"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00482-2"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.18.8724-8732.2001"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.10.045"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir349"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2019.100009"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.10.5458-5465.2004"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.23.10903-10910.2000"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv082"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-010-0677-1"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-018-0227-2"},{"key":"e_1_3_3_23_1","unstructured":"WHO. WHO | statement on the 1st meeting of the IHR emergency committee on the 2014 Ebola outbreak in West Africa [Internet]. WHO2014. [accesed 2019 Mar 6]. https:\/\/www.who.int\/mediacentre\/news\/statements\/2014\/ebola-20140808\/en\/"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170704"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1258"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005547"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.09.082"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1086\/520591"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502924"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414216"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.171389"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30242-6"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.05.097"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32621-6"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614067"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix189"},{"key":"e_1_3_3_37_1","first-page":"31246","article-title":"Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea","volume":"0264","author":"Juan-Giner A","year":"2018","unstructured":"Juan-Giner A, Tchaton M, Jemmy J-P, Soumah A, Boum Y, Faga EM, Cisse M, Grais RF. Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea. Vaccine. 2018;S0264-410X:31246\u20135.","journal-title":"Vaccine"},{"key":"e_1_3_3_38_1","first-page":"217","article-title":"The sierra leone trial to introduce a vaccine against Ebola: an evaluation of rVSV\u2206G-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak","volume":"6","author":"Samai M","year":"2018","unstructured":"Samai M, Seward JF, Goldstein ST, Mahon BE, Lisk DR, Widdowson M-A, Jalloh MI, Schrag SJ, Idriss A, Carter RJ, et al. The sierra leone trial to introduce a vaccine against Ebola: an evaluation of rVSV\u2206G-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak. J Infect Dis. 2018;6:217.","journal-title":"J Infect Dis"},{"key":"e_1_3_3_39_1","unstructured":"WHO. Strategic Advisory Group of Experts (SAGE) on immunization interim recommendations on vaccination against Ebola Virus Disease (EVD) [internet]. 2019 [accessed 2019 Jun 28]. www.who.int\/immunization\/sage\/meetings\/2019\/april\/SAGE_April_2019_meeting_summary.pdf?ua=1"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00154-1"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30165-8"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002230"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.03.004"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30242-6"},{"key":"e_1_3_3_45_1","article-title":"Pregnant women & vaccines against emerging epidemic threats [Internet]","author":"The PREVENT Working Group","unstructured":"The PREVENT Working Group. Pregnant women & vaccines against emerging epidemic threats [Internet]. Prev Work Gr. [accessed 2019 Mar 17]. https:\/\/www.who.int\/immunization\/sage\/meetings\/2018\/october\/1_PREVENT_Recs_Excerpts_for_SAGE.PDF.","journal-title":"Prev Work Gr"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12978-017-0429-8"},{"key":"e_1_3_3_47_1","unstructured":"Branswell H. Ebola vaccine will be given to pregnant women marking reversal in policy [internet]. [accssed 2019 Mar 23]. https:\/\/www.statnews.com\/2019\/02\/20\/ebola-pregnancy-reversal\/"},{"key":"e_1_3_3_48_1","unstructured":"RDC. EBOLA RDC - Evolution de la riposte contre l\u2019\u00e9pid\u00e9mie d\u2019Ebola dans les provinces du Nord Kivu et de l\u2019Ituri au Samedi 15 juin 2019 [Internet]. 2019 [accessed 2019 Jun 28]. https:\/\/mailchi.mp\/sante.gouv.cd\/ebola_kivu_15juin19?e=77c16511ad"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1086\/520591"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000225"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab3920"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61137-0"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30302-7"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30302-7"},{"key":"e_1_3_3_55_1","unstructured":"Merck. Merck begins rolling submission of licensure application for V920 (rVSV\u2206G-ZEBOV-GP) to U.S. Food and drug administration [internet]. 2018 [accessed 2019 Mar 16]. https:\/\/investors.merck.com\/news\/press-release-details\/2018\/Merck-Begins-Rolling-Submission-of-Licensure-Application-for-V920-rVSVG-ZEBOV-GP-to-US-Food-and-Drug-Administration\/default.aspx"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0329-7"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1711583"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30242-6"},{"key":"e_1_3_3_59_1","unstructured":"WHO. Ebola Virus Disease Democratic Republic of the Congo External Situation Report 17 [Internet]. 2018 [accessed 2019 Apr 9]. http:\/\/www.who.int\/ebola\/historical-outbreaks-drc\/en\/."},{"key":"e_1_3_3_60_1","unstructured":"Minist\u00e8re de la Sant\u00e9 RD du C. EBOLA RDC - Evolution de la riposte contre l\u2019\u00e9pid\u00e9mie d\u2019Ebola dans les provinces du Nord Kivu et de l\u2019Ituri au Lundi 22 juillet 2019 [Internet]. 2019 [accessed 2019 Jul 30]. https:\/\/us13.campaign-archive.com\/?u=89e5755d2cca4840b1af93176&id=1af4c6a868"},{"key":"e_1_3_3_61_1","unstructured":"WHO. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. [Internet]. 2019 [accessed 2019 Jun 14]. https:\/\/www.who.int\/csr\/resources\/publications\/ebola\/ebola-ring-vaccination-results-12-april-2019.pdf"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.su6503a14"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv532"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2508.190281"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature17949"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1137-3"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1209591110"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00669-19"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2018.06.022"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep27944"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.03.045"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.08.023"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj1701"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030002"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw389"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01931-07"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30677-1"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir298"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1995"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw256"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy565"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2101.140256"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001031"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv316"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202753"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14428"},{"key":"e_1_3_3_87_1","unstructured":"WHO | Marburg virus disease. WHO [Internet] 2017 [accessed 2019 Apr 9]. http:\/\/origin.who.int\/mediacentre\/factsheets\/fs_marburg\/en\/"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11262-017-1455-x"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.251"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00959-06"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68546-2"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1607.100159"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy293"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094355"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03122"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir350"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002600"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02516-08"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01190-17"},{"key":"e_1_3_3_100_1","unstructured":"Profectus Biosciences. Profectus biosciences awarded NIH contract for up to $22.25 million to develop multi-component vaccine for Ebola Marburg and Lassa viruses [Internet]. 2017 [accessed 2019 Mar 5]. www.profectusbiosciences.com"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S147276"},{"key":"e_1_3_3_102_1","unstructured":"Nigeria Center for Disease Control (NCDC). 2019 LASSA Fever Outbreak Situation report week 13 [Internet]. [accessed 2019 Apr 9]. https:\/\/ncdc.gov.ng\/diseases\/sitreps\/?cat=5&name=An update of Lassa fever outbreak in Nigeria"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1306615"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020183"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003736"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau9343"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0104-x"},{"key":"e_1_3_3_108_1","unstructured":"Profectus Biosciences. CEPI awards contract worth up to $36 million to profectus biosciences and emergent biosolutions to develop lassa virus vaccine [Internet]. 2018 [accessed 2019 Mar 5]. http:\/\/www.profectusbiosciences.com\/news\/releases.html"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44210-6"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01852-10"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02154-16"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.10.012"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.02.087"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/npjvaccines.2016.2"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.03.089"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010690"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2008.03.002"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.06.007"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.12.007"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4131"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.1590\/0074-02760150192"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000381"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1602180"},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29401-x"},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07502-5"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-019-00083-7"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.10.045"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01860-12"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.095"},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.11.087"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1208328"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0096-y"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.3390\/v6020516"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir379"},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00794-11"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2019.1649532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:47:30Z","timestamp":1770911250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2019.1649532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":134,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,3]]}},"alternative-id":["10.1080\/21645515.2019.1649532"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2019.1649532","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}